Inspire Medical (INSP) Q2 Revenue Up 11%

Inspire Medical Systems (NYSE:INSP), a medical device company specializing in neurostimulation systems for obstructive sleep apnea (OSA), reported its earnings for the second quarter of fiscal 2025 on August 4, 2025. The biggest news was GAAP revenue of $217.1 million, surpassing analyst estimates of $214.3 million, and non-GAAP earnings per share (EPS) of $0.45, which more than doubled consensus expectations of $0.20. However, management lowered its full-year 2025 outlook for both revenue and earnings, reflecting a slower-than-anticipated rollout of the next-generation Inspire V device and increased operating costs. Overall, the quarter featured solid sales growth and positive adjusted earnings but highlighted operational friction that will affect the remainder of the year. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Inspire Medical Systems designs neurostimulation systems that treat moderate to severe OSA in patients who are unable to tolerate continuous positive airway pressure (CPAP) devices. Its core product is the Inspire therapy system, an implantable device that uses electrical stimulation to keep a patient’s airway open during sleep. The system is a minimally invasive alternative to traditional surgical treatments and is currently the only FDA-approved neurostimulation device of its kind for OSA.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool